<DOC>
	<DOC>NCT00192764</DOC>
	<brief_summary>The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome. Patients with diffuse large-cell lymphoma are treated by high cyclophosphamide containing CHOP. The planned dose is 3000 mg/m2 which is 4 times the atandard one. Only 4 cycles are given.</brief_summary>
	<brief_title>High Dose CHOP in Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>largecell nonHodgkin's lymphoma IPI lowintermediate, highintermediate and high or bulky mediastinum age 1865 previous treatment for lymphoma serious concurrent systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>large cell lymphoma</keyword>
	<keyword>CHOP</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>high-dose</keyword>
</DOC>